Zepbound sheds more weight than Wegovy in trial, Eli Lilly says - NBC News
Dec 4, 2024 · According to Lilly’s trial results, patients who got weekly injections of Zepbound lost an average 20.2% of their body weight, or 50.3 pounds, after 72 weeks, compared with an average of 13.7% ...
Lilly's Zepbound® (tirzepatide) superior to Wegovy® …
Dec 4, 2024 · On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. i At 72 weeks, Zepbound beat Wegovy on both the primary endpoint and all five key secondary endpoints in this trial of adults living with obesity or overweight with at least one weight-related medical problem and without diabetes.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Dec 4, 2024 · While both medications showed a significant weight loss benefit, after 72 weeks on treatment, people treated with Zepbound lost 20% of their body weight, compared to people on Wegovy who lost just ...
Weight loss: Zepbound More Effective than Wegovy, Eli Lilly Says
Dec 5, 2024 · Zepbound led to more long-term weight loss than Wegovy in a new clinical trial from drugmaker Eli Lilly. Lilly officials said 31% of people taking Zepbound lost at least 25% of their body weight ...
Zepbound tops Wegovy for weight loss in Eli Lilly study
Dec 4, 2024 · Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly …
Dec 4, 2024 · Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Eli Lilly's Zepbound tops Wegovy in head-to-head weight loss trial
Dec 4, 2024 · Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly...
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity …
Dec 4, 2024 · Zepbound, an in-demand weight loss drug from Eli Lilly, helped people in a large clinical trial lose significantly more weight over 18 months than Novo Nordisk’s rival treatment Wegovy, results released by Lilly Wednesday show. The head-to-head results are a key finding that may help Lilly wrest ...
Eli Lilly's Zepbound causes greater weight loss than Novo …
Dec 4, 2024 · Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections.
Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss ...
Dec 11, 2023 · Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks